Literature DB >> 21795678

Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.

Kevin Zarrabi1, Antoine Dufour, Jian Li, Cem Kuscu, Ashleigh Pulkoski-Gross, Jizu Zhi, Youjun Hu, Nicole S Sampson, Stanley Zucker, Jian Cao.   

Abstract

Matrix metalloproteinases (MMPs) have been shown to be key players in both extracellular matrix remodeling and cell migration during cancer metastasis. MMP-14, a membrane-anchored MMP, in particular, is closely associated with these processes. The hemopexin (PEX) domain of MMP-14 has been proposed as the modulating region involved in the molecular cross-talk that initiates cell migration through homodimerization of MMP-14 as well as heterodimerization with the cell surface adhesion molecule CD44. In this study, minimal regions required for function within the PEX domain were investigated through a series of substitution mutations. Blades I and IV were found to be involved in cell migration. We found that blade IV is necessary for MMP-14 homodimerization and that blade I is required for CD44 MMP-14 heterodimerization. Cross-talk between MMP-14 and CD44 results in phosphorylation of EGF receptor and downstream activation of the MAPK and PI3K signaling pathways involved in cell migration. Based on these mutagenesis analyses, peptides mimicking the essential outermost strand motifs within the PEX domain of MMP-14 were designed. These synthetic peptides inhibit MMP-14-enhanced cell migration in a dose-dependent manner but have no effect on the function of other MMPs. Furthermore, these peptides interfere with cancer metastasis without affecting primary tumor growth. Thus, targeting the MMP-14 hemopexin domain represents a novel approach to inhibit MMP-14-mediated cancer dissemination.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795678      PMCID: PMC3190951          DOI: 10.1074/jbc.M111.256644

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

1.  MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions.

Authors:  Sophia K Khaldoyanidi; Vladislar V Glinsky; Lyudmila Sikora; Anna B Glinskii; Valerie V Mossine; Thomas P Quinn; Gennadi V Glinsky; P Sriramarao
Journal:  J Biol Chem       Date:  2002-11-15       Impact factor: 5.157

Review 2.  Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.

Authors:  Rajeshwar P Verma; Corwin Hansch
Journal:  Bioorg Med Chem       Date:  2007-01-17       Impact factor: 3.641

3.  Tissue inhibitor of metalloproteinases-2 binding to membrane-type 1 matrix metalloproteinase induces MAPK activation and cell growth by a non-proteolytic mechanism.

Authors:  Silvia D'Alessio; Giovanni Ferrari; Karma Cinnante; William Scheerer; Aubrey C Galloway; Daniel F Roses; Dmitri V Rozanov; Albert G Remacle; Eok-Soo Oh; Sergey A Shiryaev; Alex Y Strongin; Giuseppe Pintucci; Paolo Mignatti
Journal:  J Biol Chem       Date:  2007-11-08       Impact factor: 5.157

4.  The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface.

Authors:  Yoshifumi Itoh; Noriko Ito; Hideaki Nagase; Motoharu Seiki
Journal:  J Biol Chem       Date:  2008-03-12       Impact factor: 5.157

5.  Molecular dissection of the structural machinery underlying the tissue-invasive activity of membrane type-1 matrix metalloproteinase.

Authors:  Xiao-Yan Li; Ichiro Ota; Ikuo Yana; Farideh Sabeh; Stephen J Weiss
Journal:  Mol Biol Cell       Date:  2008-05-21       Impact factor: 4.138

6.  Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer.

Authors:  Jian Cao; Christian Chiarelli; Omer Richman; Kevin Zarrabi; Pallavi Kozarekar; Stanley Zucker
Journal:  J Biol Chem       Date:  2008-01-03       Impact factor: 5.157

7.  Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.

Authors:  Alessio Giubellino; Yang Gao; Sunmin Lee; Min-Jung Lee; James R Vasselli; Sampath Medepalli; Jane B Trepel; Terrence R Burke; Donald P Bottaro
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

8.  Role of the hemopexin domain of matrix metalloproteinases in cell migration.

Authors:  Antoine Dufour; Nicole S Sampson; Stanley Zucker; Jian Cao
Journal:  J Cell Physiol       Date:  2008-12       Impact factor: 6.384

Review 9.  Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Histochem Cell Biol       Date:  2008-11-13       Impact factor: 4.304

10.  Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3.

Authors:  Gabriela Magenta; Ximena Borenstein; Romina Rolando; María Adela Jasnis
Journal:  BMC Cancer       Date:  2008-02-08       Impact factor: 4.430

View more
  83 in total

1.  Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Authors:  Albert G Remacle; Vladislav S Golubkov; Sergey A Shiryaev; Russell Dahl; John L Stebbins; Andrei V Chernov; Anton V Cheltsov; Maurizio Pellecchia; Alex Y Strongin
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

2.  A role of MMP-14 in the regulation of invasiveness of nasopharyngeal carcinoma.

Authors:  Jian Zhao; Zhongyu Kong; Feng Xu; Wei Shen
Journal:  Tumour Biol       Date:  2015-06-04

Review 3.  Matrix metalloproteinase collagenolysis in health and disease.

Authors:  Sabrina Amar; Lyndsay Smith; Gregg B Fields
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-04-26       Impact factor: 4.739

4.  MT1-MMP Binds Membranes by Opposite Tips of Its β Propeller to Position It for Pericellular Proteolysis.

Authors:  Tara C Marcink; Jayce A Simoncic; Bo An; Anna M Knapinska; Yan G Fulcher; Narahari Akkaladevi; Gregg B Fields; Steven R Van Doren
Journal:  Structure       Date:  2018-11-21       Impact factor: 5.006

5.  Phosphoramidate-based peptidomimetic inhibitors of membrane type-1 matrix metalloproteinase.

Authors:  Desiree E Mendes; Annie Wong-On-Wing; Clifford E Berkman
Journal:  J Enzyme Inhib Med Chem       Date:  2015-09-04       Impact factor: 5.051

6.  miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14.

Authors:  Yiyi Li; Cem Kuscu; Anna Banach; Qian Zhang; Ashleigh Pulkoski-Gross; Deborah Kim; Jingxuan Liu; Eric Roth; Ellen Li; Kenneth R Shroyer; Paula I Denoya; Xiaoxia Zhu; Longhua Chen; Jian Cao
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 7.  The history of matrix metalloproteinases: milestones, myths, and misperceptions.

Authors:  Rugmani Padmanabhan Iyer; Nicolle L Patterson; Gregg B Fields; Merry L Lindsey
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-08-17       Impact factor: 4.733

8.  Characterization and regulation of MT1-MMP cell surface-associated activity.

Authors:  Sonia Pahwa; Manishabrata Bhowmick; Sabrina Amar; Jian Cao; Alex Y Strongin; Rafael Fridman; Stephen J Weiss; Gregg B Fields
Journal:  Chem Biol Drug Des       Date:  2018-12-19       Impact factor: 2.817

9.  Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study.

Authors:  Arthur Winer; Maxwell Janosky; Beth Harrison; Judy Zhong; Dariush Moussai; Pinar Siyah; Nina Schatz-Siemers; Jennifer Zeng; Sylvia Adams; Paolo Mignatti
Journal:  Mol Cancer Ther       Date:  2016-07-27       Impact factor: 6.261

10.  Small-molecule binding sites to explore protein-protein interactions in the cancer proteome.

Authors:  David Xu; Shadia I Jalal; George W Sledge; Samy O Meroueh
Journal:  Mol Biosyst       Date:  2016-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.